SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

Patent ExpiryPEA with LSD combinationPEA with ketamine combinationPEA with ibogaine combinationPositive

AI Analysis

Summary

SciSparc's subsidiary NeuroThera announced a collaboration with Clearmind to enhance its U.S. patent portfolio covering proprietary combinations of PEA technology with LSD, ketamine, and ibogaine for potential therapeutic applications in mental health and substance use disorders.

Outcome Details

U.S. patent applications covering proprietary combinations of PEA technology with LSD, ketamine and ibogaine

Importance:4/10

Sentiment:

0.30

patentcollaborationLSDketamineibogainemental healthPTSDdepressionsubstance use disorder

Related Companies

$SPRC $CMND

Read the original article

Published by GlobeNewswire Pharma on September 23, 2026 12:35 PM

Read Original